Table 1.
Information of participants in this trial.
| Clinical characteristics of patients subjected to IHC testing | |
|---|---|
| Characteristic | N=30 |
| Grade | |
| WHO II | 16 |
| WHO III | 14 |
| Histology | |
| Astrocytoma | 28 |
| Oligodendroglioma | 2 |
| Gender | |
| Male | 11 |
| Female | 19 |
| Age (years) | |
| Median | 44 |
| Range | 13-63 |
| Location | |
| Frontal lobe | 13 |
| Temporal lobe | 5 |
| Parietal lobe | 2 |
| Multiple lobes | 10 |
| Overall survival (days) | |
| Median | 637.5 |
| Range | 44-1091 |
| Clinical characteristics of other participants. | |
| Characteristic | N=38 |
| Grade | |
| Normal brain tissues | 6 |
| WHO II | 15 |
| WHO III | 17 |
| Histology | |
| Astrocytoma | 29 |
| Oligodendroglioma | 3 |
| Gender | |
| Male | 22 |
| Female | 16 |
| Age (years) | |
| Median | 48 |
| Range | 15-73 |
| Location | |
| Frontal lobe | 14 |
| Temporal lobe | 13 |
| Lateral ventricle | 2 |
| Multiple lobes | 9 |